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ABSTRACT 
Background: The association between bone mineral density (BMD) and serum 25[OH]D 
concentration is weak, particularly in certain races (e.g. Black African vs. Caucasian) and in 
athletic populations. We aimed to examine if bioavailable vitamin D rather than serum 25[OH]D 
was related to markers of bone health within a racially diverse athletic population. 
Methods: In 604 male athletes [Arab (n=327), Asian (n=48), Black (n=108), Caucasian (n=53) & 
Hispanic (n=68)], we measured total 25-hydroxyvitamin D (25[OH]D), vitamin D–binding 
protein, and bone mineral density (BMD) by (DXA). Bioavailable vitamin D was calculated using 
the free hormone hypothesis. 
Results: From 604 athletes, 21.5% (n=130) demonstrated severe 25[OH]D deficiency, 37.1% 
(n=224) deficiency, 26% (n=157) insufficiency and 15.4% (n=93) sufficiency. Serum 25[OH]D 
concentrations were not associated with BMD at any site.  After adjusting for age and race, 
bioavailable vitamin D was associated with BMD (spine, neck and hip). Mean serum vitamin D 
binding protein concentrations were not associated with 25[OH]D concentrations (p=0.392). 
Conclusion: Regardless of age or race, bioavailable vitamin D and not serum 25[OH]D was 
associated with BMD in a racially diverse athletic population. If vitamin D screening is warranted, 
clinicians should use appropriate assays to calculate vitamin D binding protein and bioavailable 
vitamin D levels concentrations than serum 25[OH]D. In turn, prophylactic vitamin D 
supplementation to ‘correct’ insufficient athletes should not be based upon serum 25[OH]D 
measures.  
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INTRODUCTION 
Vitamin D3 (cholecalciferol) is a lipophilic pro-hormone produced in the skin from exposure to 
sunlight. Cholecalciferol is transported bound to vitamin D-binding protein (DBP), and is 
hydroxylated in the liver to form 25-hydroxyvitamin D (25[OH]D). 25[OH]D undergoes further 
hydroxylation in the kidney, to form the active hormone 1, 25-dihydroxyvitamin D [1,25(OH)2D]. 
This bioactive metabolite, regulates intestinal calcium absorption, bone calcium resorption and 
renal calcium reabsorption to maintain calcium homeostasis, and promote skeletal mineralisation 
(1, 2). Accordingly, skeletal pathologies such as rickets and osteomalacia often present when 
25[OH]D levels are consistently deficient (3).  
 
Clinically to date, measuring serum 25[OH]D concentration provides the best estimate of vitamin 
D status as both circulating levels of cholecalciferol and 1,25(OH)2D have short half-lives, 
approximately 24hrs and 4-6hrs, respectively (4, 5). Serum cholecalciferol levels can also be 
affected by recent sunlight exposure, and is difficult to measure due to the lipophilic nature of the 
molecule. Optimum concentrations of serum 25[OH]D for skeletal health are still debated (7). 
Many clinicians define vitamin D sufficiency as the lowest serum 25[OH]D concentration that 
maximally suppresses parathyroid hormone (PTH) secretion and/or optimises bone mineral 
density (BMD) (6-8). The generally accepted serum 25[OH]D concentration ranges are: severely 
deficient (<10 ng/mL), deficient (10–20 ng/mL), insufficient (20–30 ng/mL), or sufficient (>30 
ng/mL); although of evidence supporting these categories are derived from elderly cohorts or 
groups with existing skeletal disorders (9-12).  
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Association between bone mineral density (BMD) and serum 25[OH]D concentration is weak  (13-
17). Our group previously demonstrated no association between serum 25[OH]D and markers of 
bone health in weight bearing athletes of different racial background, suggesting that markers of 
bone health are independent of serum 25[OH]D concentrations (18). It appears there is a 
‘paradoxical relationship’ between race and vitamin D concentration that has largely been ignored, 
i.e. black individuals generally have the lowest serum 25[OH]D concentrations but the greatest 
BMD and reduced risk of fracture (14, 19). DBP may provide an insight as to why certain racial 
groups have distinct 25[OH]D and BMD relationships (20). DBP is the primary vitamin D carrier, 
binding 85%–90% of total circulating 25[OH]D, with the remaining unbound 25[OH]D considered 
to be bioavailable (21). Polymorphisms in the DBP coding genes (specifically rs4588 and rs7041) 
produce proteins that differ in affinity for 25[OH]D, and it is these polymorphisms that are known 
to differ between racial groups (22). Differentiating between total vitamin D (measured as 
25[OH]D) and bioavailable vitamin D is crucial, given that the latest evidence suggests that DBP 
inhibits certain actions of vitamin D, since the bound fraction is unavailable to act on target cells. 
(20, 21, 23). Consequently, serum bioavailable vitamin D may have a better association with bone 
health than serum 25[OH]D concentration (20). To date, research on vitamin D status in athletes 
has focused solely upon serum 25[OH]D and as a consequence, the current advice and guidelines 
given to athletes and clinicians treating vitamin D deficiency may be inaccurate. Therefore, the 
present study set out to examine if bioavailable vitamin D is related to markers of bone health 
within a racially diverse athletic population. It was hypothesised that bioavailable vitamin D and 
not serum vitamin D would be associated with markers of bone health in a racially diverse athlete 
population. 
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METHODS 
Participants 
Six hundred and four male athletes registered with the Qatar Olympic Committee (QOC) [Arab 
(n=327), Asian (n=48), Black (n=108), Caucasian (n=53) and Hispanic (n=68)], exercising ≥6 
h/week, presented for pre-competition medical assessment at Aspetar Sports Medicine Hospital, 
Qatar. All athletes undertook dual-energy X-ray absorptiometry for assessment of their bone 
mineral density, and a blood test to assess serum 25[OH]D concentration and vitamin D-binding 
protein. No athlete was taking vitamin D supplementation upon recruitment. Ethical approval was 
obtained from Qatar Anti-Doping Laboratory IRB (#F2014000062).  
 
Laboratory Analyses 
Serum 25-Hydroxyvitamin D (25[OH]D) and Parathyroid hormone (PTH) 
Venous blood samples were collected from athletes following an overnight fast.  The blood sample 
was separated into two aliquots (5mL SST tubes) of serum for analysis of 25[OH]D and one aliquot 
of plasma for PTH assessment. Samples were centrifuged for 10 minutes at 3000 RPM. Serum 
25[OH]D was analysed utilising chemiluminescent immunoassay technology with sensitivity set 
at 7 ng/mL (Liaison® 25-OH Vitamin-D Total Assay; Diasorin Inc., Saluggia (Vercelli), Italy). 
The intra- and interassay CV was 7.6–9.4% and 9.8–13.4%, respectively. Based upon the serum 
25[OH]D results, athletes were placed into four 25[OH]D categories; severely deficient (<10 
ng/mL), deficient (10–20 ng/mL), insufficient (20–30 ng/mL), or sufficient (>30 ng/mL). Levels 
of intact PTH were measured with the use of the DiaSorin Liaison analyzer, chemiluminescence 
immunoassay (CLIA). The inter-assay CV was 2.5%. 
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Vitamin D-Binding Protein  
Serum vitamin D-binding protein (DBP) concentrations (µg/mL) were determined using a 
commercially available kit (R&D Systems, UK). The limit of sensitivity was ≤0.65 ng.mL-1 and 
an inter-assay coefficient of variation was 7.2%. An automatic enzyme-linked immunosorbent 
assay (ELISA) microplate reader (Infinite®200-PRO NanoQuant, Switzerland) and computer 
software Magellan Standard (v7.1) were used to analyse DBP. 
 
Assessment of Bone Mineral Density 
Dual-energy x-ray absorptiometry (Osteocore III, Perols, France, v5.22b) scanning was used to 
assess hip, femoral neck and lumbar spine bone mineral density (BMD). A certified technologist 
from the International Society of Clinical Densitometry performed all calibrations and 
measurements. Quality assurance was performed each morning before testing. The coefficient of 
variation for these records is <1.01% in Aspetar. BMD was calculated in g/cm2 for spine (L2–L4), 
hip-neck and hip-total. In addition, the clinical age-matched and gender-specific Z-score index 
was used to classify the BMD. T-scores were calculated for those athletes older than 20 years as 
per WHO recommendations (24).  
 
Calculation of Bioavailable 25-Hydroxyvitamin D 
Bioavailable and DBP-bound 25[OH]D were calculated using equations from material provided 
by Powe et al., 2013 (20), and adapted from those described by Vermeulen and colleagues (25). 
These methods use the free hormone hypothesis to define bioavailable hormone, as the fraction 
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that is both free and albumin-bound, i.e., the fraction not bound to circulating binding proteins 
such as DBP. Free levels of 25[OH]D were calculated using the following equation: 
[Dfree]  =
[DDBP]
KDBP
[𝑇𝑜𝑡𝑎𝑙 𝐷𝐵𝑃] − [DDBP]
 
 
After calculating free 25-hydroxyvitamin D, we used equation 2 to calculate the concentration of 
bioavailable (non-DBP bound vitamin):  
[Bio D] = [Dfree] + [DAlb] = (Kalb ∗ [𝐴𝑙𝑏] + 1) ∗ [DFree] ) 
Definitions 
[DFree] = concentration of free (unbound) 25[OH] D 
[DDBP] = concentration of vitamin D-binding protein-bound 25[OH] D 
KDBP = genotype-nonspecific affinity constant between 25[OH] D and DBP = 0.7 x 10
9 M-1 
[Total DBP] = concentration of serum DBP in g/L 
[Bio D] = concentration of bioavailable D 
[DAlb] = concentration of albumin-bound vitamin D 
Kalb = affinity constant between vitamin D and albumin = 6 x 105 M-1 
Alb = albumin 
 
Statistics 
All data were coded and analysed using the SPSS (v21.0). Descriptive statistics were presented as 
mean and standard deviation (SD) for continuous variables. For categorical variables, frequency 
and percentage were reported. 25[OH]D data were skewed therefore a natural log-transformation 
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was applied prior to analysis. A one-way analysis of variance was performed to assess 
anthropometric differences between the four 25[OH]D groups (<10 ng/mL, 10-20 ng/mL, 20-30 
ng/mL and >30 ng/mL). A post-hoc analysis with Bonferroni correction was used for further 
comparisons in the event of significance. To determine the relationship of bone health parameters 
with serum 25[OH]D, DBP and bioavailable 25[OH]D, Pearson’s correlation coefficient was 
determined. Multiple linear regression analysis including covariates such as age and race was 
performed with bone health as a dependent variable. Parameter estimates along with 95% 
Confidence Intervals (CI) were reported. . Power and sample size calculations recommended that 
543 subjects are sufficient for multiple regression to detect an effect size (Cohens f2) as small as 
0.02 with a significant alpha=0.05 and a statistical power 0.80 given only 3 predictors. A p-
value<0.05 was used as a cut-off for statistical significance. 
 
RESULTS 
Participants 
From 604 athletes, 21.5% (n=130) demonstrated severe 25[OH]D deficiency, 37.1% (n=224) 
deficiency, 26% (n=157) insufficiency and 15.4% (n=93) sufficiency. There was no difference in 
athlete age or body mass index across the four vitamin D status categories. However, 25[OH]D 
sufficient (>30ng/mL) athletes presented with significantly lower body fat % compared to 
insufficient (P=0.024), deficient (P=0.002) and severely deficient (P=0.001) athletes. Markers of 
bone health were normal for all athletes across all sites. 
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 Vitamin D–Binding Protein, Bioavailable Vitamin D and Markers of Vitamin D Status 
Whilst there was a positive linear association between 25[OH]D status and bioavailable vitamin 
D (r=0.702; p<0.001), DBP concentration was not associated with 25[OH]D concentrations (r=-
0.035, p=0.392).  PTH was significantly greater in severely 25[OH]D deficient athletes compared 
to insufficient (P=0.010), deficient (P=0.005) and sufficient (P<0.001) athletes. Albumin was 
significantly greater in sufficient athletes compared to 25[OH]D deficient athletes (P=0.029) 
(Table 1). Bioavailable vitamin D showed a strong association with DBP (r =-0.733; P<0.001) and 
PTH (r =-0.310; P<0.001) but not with 1,25[OH]2D (r=-0.023, P=0.738). 
 
Impact of Race upon Serum 25[OH]D, Bioavailable Vitamin D and BMD 
Mean serum 25[OH]D concentrations significantly differed between race, with Caucasians and 
Hispanics presenting greater serum 25[OH]D levels than Arabs, Asians and Blacks (Table 2). 
Whilst 1,25(OH)2D and PTH were not significantly different between racial groups, DBP was 
significantly lower in Black athletes compared to in Arabs (P<0.001), Caucasian (P<0.001) and 
Hispanic (P<0.001) athletes.  Arab athletes presented with significantly lower bioavailable 
25[OH]D concentrations compared to Black (P<0.001), Caucasian (P<0.001) and Hispanic 
(P<0.001) athletes. Arab athletes demonstrated significantly lower BMD scores across all sites 
(spine (P<0.001), neck (P<0.001) and total hip (P<0.001) compared to Caucasians, Blacks and 
Hispanic athletes. There was no difference in BMD across all sites between Black, Caucasian and 
Hispanic athletes. Finally, 25[OH]D sufficient Arab athletes presented with higher spine BMD 
than severely deficient Arabs athletes (p=0.036; 1.39 vs. 1.24 g/cm3 respectively); this was not 
observed in any other race. 
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Relationship between Markers of Bone Health, Serum 25[OH]D, PTH and Bioavailable 
Vitamin D 
Serum 25[OH]D, DBP and bioavailable vitamin D showed skewed distributions and were 
logarithmic transformed in order to meet the assumptions of the parametric statistical techniques. 
P-values and parameter estimates presented are based on log-transformed data. The age and 
ethnicity adjusted spine BMD increased [B=0.032 95% CI (0.012 to 0.051); P=0.001] with each 
one log unit change in bioavailable vitamin D.  
 
Similarly, bioavailable vitamin D was also associated with spine [B=0.032 95% CI (0.012 to 
0.051), P=0.001], neck [B=0.037 95% CI (0.016 to 0.057), P<0.001] and hip [B=0.035 95% CI 
(0.016 to 0.055), P<0.001] BMD (Table 3). DBP was negatively associated with spine [B=-0.035 
95% CI (-0.059 to -0.012), P=0.004], neck [B=-0.040 95% CI (-0.065 to -0.016), P=0.001] and hip 
[B=-0.037 95% CI (-0.061 to -0.014), P=0.002] BMD. Serum 25[OH]D concentrations were not 
associated with BMD at any site.  DBP was positively associated with neck (P=0.034) and hip T-
score (P=0.040) but not spine (P=0.067). Serum 25[OH]D and bioavailable 25[OH]D were not 
associated with T-score at any site .  PTH was not associated with BMD across all sites and T-
scores of Spine (r=-0.029, P=0.641), Hip (r=-0.093, P=0.134) and Neck (R=-0.117, P=0.061). 
 
 
 
11 
 
 
DISCUSSION 
The aim of the present study was to examine if bioavailable vitamin D was related to markers of 
bone health within a racially diverse athlete population. It was observed that after adjusting for age 
and race, bioavailable vitamin D was closely associated with BMD (spine, neck and hip), whilst 
there was no association between serum 25[OH]D concentration and BMD at any site .  DBP was 
positively associated with neck and hip T-scores but not spine. Serum 25[OH]D and bioavailable 
25[OH]D were not associated with T-scores at any site. Furthermore, mean serum DBP 
concentrations were not associated with 25[OH]D concentrations.  For clinicians treating vitamin 
D insufficiency based on serum 25(OH)D measures, our data suggests that the current choice of 
assay is not fit for practice when examining the relationship between bone health and vitamin D 
concentrations.  
 
The Role of Bioavailable Vitamin D upon Markers of Bone Health 
Vitamin D is just one of many factors including energy availability and weight bearing exercise 
that can impact upon bone health. The role of vitamin D and calcium in bone development, growth 
and integrity have been well documented (1). Previous studies however, demonstrate inconsistent 
associations between serum 25[OH]D concentrations and BMD in general (16, 17) and athletic 
populations (26). It has be postulated that the osteogenic effect of weight-bearing exercise (i.e. 
loading the bones) may be sufficient to maintain markers of bone health, irrespective of 25[OH]D 
status in healthy adults (27, 28). Though the present data also suggests that the clinical utilisation 
of serum 25[OH]D could be an additional factor for this inconsistency, given that bioavailable 
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vitamin D and not serum 25[OH]D was associated with BMD at all sites in an racially diverse 
athletic population. Using the free hormone hypothesis, the unbound fraction (or bioavailable 
vitamin D) may exert a stronger biological effect on BMD than total 25[OH]D (21, 23). Since 
serum 25[OH]D is generally used in previous observational and interventional studies, it may 
explain such inconsistencies in the poor association between serum 25[OH]D and BMD (29, 30). 
Accordingly, our data supports the notion that current 25[OH]D reference ranges provide an 
inaccurate representation of true vitamin D status in athletes. In contrast to previous findings, DBP 
concentration was not associated with 25[OH]D concentrations (p=0.392) (29). Whilst there was 
a positive linear association between 25[OH]D status and bioavailable vitamin D, PTH levels were 
not associated with 25[OH]D levels, BMD or T-scores, suggesting that the association between 
bioavailable 25[OH]D levels and BMD is not mediated via PTH. 
 
Impact of Race 
Studies support that racial differences or a ‘paradox’ exists in the relationship between serum 
25[OH]D concentrations and markers of bone health  (14, 31, 32). Specifically, recent studies in 
the general population have demonstrated that polymorphisms in the DBP gene were associated 
with corresponding changes in total 25[OH]D levels and the risk of osteoporosis (22, 33). 
Aggarwal et al. demonstrated that bioavailable 25[OH]D was a better measure of vitamin D status 
with respect of BMD in patients with nephrotic syndrome (34). To our knowledge, this is the first 
study to examine DBP and bioavailable vitamin D alongside bone health as assessed by DXA in 
athletes. Our data supports these previous observations, with Hispanic athletes presenting with 
greater mean serum 25[OH]D levels (32.1 ng/mL) compared to Caucasian (26.2ng/mL) and Black 
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(19.9ng/mL) athletes, despite no difference in bioavailable vitamin D or BMD at any site. 
Bioavailable vitamin D is determined by vitamin D-binding protein concentration, which is 
encoded by the group-specific component (GC) gene (35). Polymorphisms in the GC gene, 
produce proteins that differ in affinity for 25[OH]D, and it is these polymorphisms that are known 
to differ between racial groups. Racial differences in the prevalence of common genetic 
polymorphisms provide a likely explanation for this observation. Consequently, our data have 
implications for the wider general population, with further research warranted an adolescent and 
female athletes. 
 
Financial Considerations for Treating Clinicians 
Screening athlete for vitamin D insufficiency is expensive. In our facility, 25[OH]D assessment 
costs $255USD per athlete. Since Aspetar screens approximately 1500 elite athletes per year, 
systematic 25[OH]D screening costs our facility $382,500USD per year.  Since our data clinically 
questions the value of routine 25[OH]D screening, the financial burden of vitamin D testing only 
adds weight to the debate of whether clinicians should be testing for vitamin D insufficiency, since 
all athletes in the present study demonstrated normal bone health. Our data also questions the value 
of prophylactic vitamin D supplementation (typically 2000IU/d oral cholecalciferol) in insufficient 
athletes to ‘correct’ 25[OH]D status, but who show no symptoms of relative energy deficiency 
syndrome, poor bone health or musculoskeletal injury. Perhaps targeted vitamin D screening and 
supplementation should be reserved for those athletes presenting with stress fracture related 
injuries, or those competing in non-weight bearing sports such as cycling and swimming where 
the osteogenic effect of bone loading is sub-optimal. If testing is warranted however, clinicians 
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should use the appropriate assays to calculate DBP and bioavailable vitamin D status rather than 
serum 25[OH]D.  
 
Limitations 
The primary limitations of this study are the lack of data on DBP polymorphisms across racial 
groups and the cross-sectional design. The equations used to calculate free and bioavailable 
25[OH]D in this study used the affinity constants of the Gc1F allele, as did the equations in Powe 
et al. (29). Whilst we acknowledge that training volume and intensity were not recorded, athletes 
were only included in the study if they were registered with the QOC, competed at national or 
international level and trained for more than 6 h per week. We also acknowledge that serum 
25[OH]D measurement only offered a snapshot of current status. Thus, it is entirely possible for 
severely deficient (<10 ng/mL) and deficient (10-20 ng/mL) athletes in the present study to have 
spent many years sufficient (>30 ng/mL) prior to recruitment. An additional limitation is that only 
male athletes were studied, due to a lack of female athletes presenting for pre-competition medical 
assessment at the time of data analysis. Finally, the impact of training load and dietary intake data, 
to assess total energy and calcium intake, and the assessment of steroid hormones were not 
accounted for in this study. Although, our previous research reports no association between 
25[OH]D and bone health (26), future longitudinal trials including genotype-specific binding 
affinity constants in the calculation for bioavailable vitamin D, training, dietary and hormone 
analysis in racially diverse populations are warranted. 
 
CONCLUSION 
15 
 
In conclusion, regardless of age or race, bioavailable vitamin D and not serum 25[OH]D was 
associated with BMD in a racially diverse athletic population. Our data questions the value of 
routine 25[OH]D screening in athletes, since all athletes in the present study demonstrated 
clinically normal bone health, despite 85% of athletes presenting with either serum 25[OH]D 
insufficiency, deficiency or severe deficiency, respectively. This study suggests that bioavailable 
vitamin D, rather than the current standard of 25[OH]D is a better measure of vitamin D status 
with respect to BMD.  
 
What are the findings? 
• This study demonstrated that in a racially diverse athletic population, bioavailable vitamin 
D was closely associated with bone mineral density (BMD; spine, neck and hip).  
• No association was observed between serum 25[OH]D concentration and BMD at any site.   
• Mean serum DBP concentration were not correlated with 25[OH]D concentrations 
(p=0.392).   
 
How might it impact on clinical practice in the near future? 
• Determining bone health is multifactorial. Systematic screening to determine 25[OH]D 
concentrations in isolation is expensive, and demonstrates a poor relationship to bone 
health in an racially diverse athletic population.  
• If testing is warranted, clinicians should use the appropriate assays to calculate DBP and 
bioavailable vitamin D concentration rather than total serum 25[OH]D.  
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• Screening athlete for vitamin D insufficiency is expensive. Targeted vitamin D screening 
and supplementation should be reserved for those athletes presenting with relative energy 
deficiency syndrome or those competing in non-weight bearing sports, such as cycling and 
swimming, where the osteogenic effect of bone loading is sub-optimal. 
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Table 1: Measures of vitamin D, albumin and parathyroid hormone against 25[OH]D status categories  
 
Vitamin D category (ng/mL) 
Severely Deficient 
<10 
(n=130) 
Deficient 
10-20 
(n=224) 
Insufficient 
20-30 
(n=157) 
Sufficient 
>30 
(n=93) 
Age Mean (SD) 23.7 (5.4) 24.6 (5.6) 25.4 (5.6) 25.0 (4.5) 
Body mass index Mean (SD) 23.6 (3.9) 24.7 (3.4) 24.2 (3.5) 24.0(3.6) 
Race n (%)     
Arab (n=327) 96 (29.4) 146 (44.6) 65 (19.9) 20 (6.1) 
Asian (n=48) 10 (20.8) 17 (35.4) 14 (29.2) 7 (14.6) 
Black (n=108) 17 (15.7) 43 (39.8) 32 (29.6) 16 (14.8) 
Caucasian (n=53) 4 (7.5) 13 (24.5) 20 (37.7) 16 (30.2) 
Hispanic (n=68) 3 (4.4) 5 (7.4) 26 (38.2) 34 (50.0) 
Blood markers (mean±SD)     
1,25(OH)2D 39.3 (14.3) 39.4 (14.9) 39.9(14.0) 34.9(9.9) 
ALB (g/L) 42.1(2.4) 41.8 (2.4) 41.9(2.5) 42.6(2.8) b 
PTH (pg/ml) 67.2 (50.8) bcd 52.9(16.2) 50.1(14.0) 41.3(8.3) 
DBP (μg/ml) 478.5 (410.4) 385.1(304.0) 416.6(298.4) 370.5(327.1) 
Bioavailable 25[OH]D (ng/mL) 0.7 (0.5) 1.5(0.9) a 2.6(1.7) ab 4.7(3.0) abc 
ALB; albumin, PTH; parathyroid hormone, DBP; vitamin D binding protein.  
a: significantly greater than <10ng/mL, b: significantly greater than 10-20ng/mL, c: significantly greater than 20-30ng/mL and d: 
significantly greater than >30ng/mL.  
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Table 2. Measures of vitamin D, BMD, albumin and parathyroid hormone by athlete race (Mean±SD) 
 Athlete Race 
 
Arab [A] 
(n=328) 
Asian  [B] 
(n=48) 
Black [C] 
(n=108) 
Caucasian [D] 
(n=53) 
Hispanic [E] 
(n=35) 
25[OH]D 15.9(8.8) 19.3 (11.8) 19.9 (10.4)a 26.2 (12.9)abc 32.1 (13.5)abcd 
1,25(OH)2D 39.6(14.7) 39.8 (14.4) 39.3 (14.6) 38.8 (10.4) 33.0 (11.7) 
ALB (g/L) 41.8(2.32) 42.2 (2.1) 41.2 (2.5) 43.3 (2.6)ac 43.1 (2.7)ac 
PTH (pg/ml) 60.7(39.5) 47.7 (11.1) 52.1 (15.4) 47.2 (14.9) 41.2 (8.2) 
DBP (μg/ml) 449.8(314.6)c 376 (176.0) 288.2 (336.1) 422.2 (372.8)c 434.2 (416.4)c 
Bioavailable 25[OH]D (ng/mL) 1.5(1.3) 1.7 (1.2) 3.3(2.7)ab 2.5 (1.7)a 3.3 (2.8)ab 
Spine BMD 1.29 (0.21) 1.32 (0.16) 1.48(0.16)ab 1.50 (0.13)ab 1.45 (0.14)ab 
Neck BMD 1.25 (0.21) 1.31 (0.19) 1.48 (0.17)ab 1.43 (0.14)ab 1.41 (0.17)ab 
Hip BMD 1.26 (0.20) 1.31 (0.18) 1.47 (0.17)ab 1.40 (0.13)ab 1.40 (0.15)ab 
Total BMD 1.26 (0.16) 1.28 (0.10) 1.43 (0.13)ab 1.42 (0.10)ab 1.38 (0.10)ab 
Spine T-score 0.61 (1.20) 0.64 (1.19) 1.85 (1.43)ab 1.98 (1.33)ab 1.74 (1.16)ab 
Neck T-score 1.22 (1.42) 1.53 (1.49) 2.72 (1.65)ab 2.25 (1.37)a 2.44 (1.42)ab 
Hip T-score 1.02 (1.20) 1.20 (1.23) 2.18 (1.41)ab 1.68 (1.07)a 2.00 (1.12)ab 
Total T-score 0.63 (1.21) 0.67 (0.96) 2.06 (1.39)ab 1.78 (1.24)ab 1.72 (1.07)ab 
ALB; albumin, PTH; parathyroid hormone, DBP; vitamin D binding protein, BMD; bone mineral density. a: significantly greater than 
Arabs, b: significantly greater than Asian, c: significantly greater than Blacks and d: significantly greater than Caucasians. 
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Table 3. Parameter estimates (β 95% CI) of association of log transformed vitamin D parameters against independent bone health 
variables (spine, neck and hip BMD and T-scores) after adjusting for age and race 
 Dependent 
variables 
 
Vitamin D parameters 
 Serum 25[OH]D 
B (95% CI) 
P value  
DBP 
B (95% CI) 
P value 
 Bioavailable 25[OH]D 
B (95% CI) 
P 
value 
Spine BMD  0.022 (-0.007 to 0.052) 0.141  -0.035 (-0.059 to -0.012) 0.004 
 
0.032 (0.012 to 0.051) 0.001 
Neck BMD  0.028 (-0.002 to 0.059) 0.071  -0.040 (-0.065 to -0.016) 0.001 
 
0.037 (0.016 to 0.057) <0.001 
Hip BMD  0.029 (0.000 to 0.059) 0.051  -0.037 (-0.061 to -0.014) 0.002 
 
0.035 (0.016 to 0.055) <0.001 
Spine T-score  -0.030 (-0.229 to 0.170) 0.770  -0.151 (-0.313 to 0.011) 0.067 
 
0.078 (-0.055 to 0.211) 0.250 
Neck T–score  -0.006 (-0.244 to 0.231) 0.957  -0.209 (-0.401 to -0.016) 0.034 
 
0.119 (-0.038 to 0.277) 0.138 
Hip T-score  0.000 (-0.198 to 0.198) 1.000  -0.169 (-0.329 to -0.008) 0.040 
 
0.098 (-0.034 to 0.230) 0.144 
* log transformed covariates and adjusted for age and ethnicity 
B: Unstandardised coefficient and (95 % confidence intervals.) 
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